Liege - Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces today that, as a result of the senior secured convertible facilities agreement and conversion agreement entered into by the Company and announced on 8 August 2022, and in accordance with condition 5(b) of the Company's EUR 125,000,000 senior unsecured convertible bonds due 2025 (ISIN: BE6325746855), the conversion price of the bonds has been adjusted from EUR 25.1917 to EUR 24.5425, effective as of 8 August 2022.

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle, Mithra is now focusing on its second product Donesta, the next-generation hormone therapy.

Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormonedependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liege, Belgium.

Contact:

Benoit Mathieu

Tel: +32 473 35 80 18

Email: investorrelations@mithra.com

(C) 2022 Electronic News Publishing, source ENP Newswire